Cardiogenesis (cgcp) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiogenesis (cgcp)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joy who wrote (15)	10/16/1997 12:43:00 PM
From: John Martin	of 66

CardioGenesis Reports Results for the Third Quarter Ended September 30, 1997 Highlights * Q3 1997 sales $1.2 million, 9.5 percent increase over Q3 1996. * Sales for nine months to date $5.5 million, 86 percent increase over same period last year. * Total procedures with the Percutaneous Myocardial Revascularization (PMR(TM)) System reach 50. * CardioGenesis PMR patients are all doing well; treatment by experienced physicians is taking less than one hour. * Cardiologists at fall medical conferences respond enthusiastically to the PMR System. * Intraoperative prospective randomized U.S. clinical trial data continues to look promising. biz.yahoo.com zacks.com Zack's earning surprise bottom of the barrel: . . . at the Bottom of the Surprises #7th on the list for today ticker company_name time reported EPS % Surprise CGCP CARDIOGENESIS 8:07 $-0.42 -23.53%

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next